John Higgins Buys Shares of OmniAb, Inc.
John Higgins purchased 40,000 shares of OmniAb, Inc. on June 17, 2026.
Key Points
- John Higgins bought 40,000 shares of OmniAb, Inc. on June 17, 2026, as part of an insider transaction.
- OmniAb, Inc. (NASDAQ: OABI) has a market cap of $339.2 million, with shares trading near $2.34.
- Several funds, including BlackRock and Geode Capital, adjusted their positions in OmniAb recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Higgins, an insider at OmniAb, Inc., purchased 40,000 shares of the company's stock on June 17, 2026. This insider transaction did not specify a purchase price, and it's part of ongoing activity among company insiders.
Other Institutional Activity in OmniAb
BlackRock, Inc. increased its holdings in OmniAb by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.7 million. Geode Capital Management, LLC also added to its position, acquiring 202,887 shares, ending with 2,925,579 shares worth about $4.59 million. Conversely, Cadian Capital Management, LP reduced its stake by 277,825 shares, now holding 4,157,129 shares valued at $6.53 million.
OmniAb, Inc. Stock Down 47.7%
Shares of OmniAb, Inc. (NASDAQ: OABI) traded near $2.34. The company has a market cap of approximately $339.2 million and a beta of 1.146, indicating moderate volatility. Over the past year, the stock has seen a low of $1.30 and a high of $2.79. The 50-day moving average is $1.97, while the 200-day moving average stands at $1.80. OmniAb maintains a strong liquidity position with a current ratio of 4.801 and a quick ratio of 4.549.
$OABI stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
OmniAb reported revenue of $28.94 million, showing a growth of 2.47%. However, the company is not profitable, with a net margin of -187.59% and a return on equity of -20.25%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at OmniAb, Inc.
In addition to John Higgins, several other insiders were active on June 17, 2026. Jennifer Cochran bought 40,000 shares and sold 20,000 shares, while Carolyn Bertozzi acquired 60,000 shares and sold 20,000 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on OmniAb. HC Wainwright & Co. reiterated its buy rating with an $11.00 price target on March 19, 2025. Benchmark maintained its buy rating with a $6.00 target on March 20, 2025. The consensus target price among analysts is $7.33, based on six opinions.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology company based in Emeryville, California. It licenses technology for discovering therapeutics to pharmaceutical and biotech companies worldwide. The company’s platform uses engineered transgenic animals to screen and create diverse antibody repertoires, aiding in drug development. OmniAb's CEO is Matthew W. Foehr, and the company employs about 89 people.
Bottom Line
John Higgins' recent purchase of OmniAb shares highlights ongoing insider interest in the company. Investors keep an eye on such insider activities as potential indicators of confidence in the company's prospects. Remember, insider transactions are disclosed after the fact and may not reflect current positions.
Get OmniAb, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OABI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.